Fairview Capital Investment Management’s Novo Nordisk NVO Stock Holding History

Fairview Capital Investment Management’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$794K	Buy	16,570 +500	+3%	+$21.5K	0.04%	123
2026 Q1	$591K	Hold	16,070	–	–	0.03%	124
2025 Q4	$818K	Hold	16,070	–	–	0.04%	103
2025 Q3	$892K	Hold	16,070	–	–	0.05%	102
2025 Q2	$1.11M	Hold	16,070	–	–	0.06%	92
2025 Q1	$1.12M	Hold	16,070	–	–	0.06%	88
2024 Q4	$1.38M	Hold	16,070	–	–	0.07%	81
2024 Q3	$1.91M	Hold	16,070	–	–	0.1%	74
2024 Q2	$2.29M	Hold	16,070	–	–	0.13%	71
2024 Q1	$2.06M	Hold	16,070	–	–	0.12%	77
2023 Q4	$1.66M	Hold	16,070	–	–	0.1%	75
2023 Q3	$1.46M	Hold	16,070	–	–	0.09%	78
2023 Q2	$1.3M	Hold	16,070	–	–	0.08%	81
2023 Q1	$1.28M	Hold	16,070	–	–	0.08%	83
2022 Q4	$1.09M	Hold	16,070	–	–	0.07%	84
2022 Q3	$800K	Hold	16,070	–	–	0.06%	81
2022 Q2	$895K	Hold	16,070	–	–	0.06%	80
2022 Q1	$892K	Hold	16,070	–	–	0.06%	80
2021 Q4	$899K	Hold	16,070	–	–	0.06%	81
2021 Q3	$771K	Hold	16,070	–	–	0.05%	82
2021 Q2	$673K	Hold	16,070	–	–	0.05%	84
2021 Q1	$541K	Hold	16,070	–	–	0.02%	123
2020 Q4	$561K	Hold	16,070	–	–	0.02%	107
2020 Q3	$557K	Hold	16,070	–	–	0.03%	101
2020 Q2	$526K	Hold	16,070	–	–	0.03%	99
2020 Q1	$483K	Hold	16,070	–	–	0.03%	103
2019 Q4	$465K	Hold	16,070	–	–	0.02%	109
2019 Q3	$415K	Hold	16,070	–	–	0.02%	118
2019 Q2	$410K	Hold	16,070	–	–	0.02%	118
2019 Q1	$420K	Hold	16,070	–	–	0.02%	113
2018 Q4	$370K	Hold	16,070	–	–	0.02%	114
2018 Q3	$379K	Hold	16,070	–	–	0.02%	110
2018 Q2	$371K	Hold	16,070	–	–	0.02%	102
2018 Q1	$395K	Hold	16,070	–	–	0.02%	93
2017 Q4	$431K	Hold	16,070	–	–	0.03%	88
2017 Q3	$387K	Hold	16,070	–	–	0.02%	89
2017 Q2	$345K	Hold	16,070	–	–	0.02%	89
2017 Q1	$275K	Hold	16,070	–	–	0.02%	82
2016 Q4	$288K	Hold	16,070	–	–	0.02%	75
2016 Q3	$334K	Hold	16,070	–	–	0.03%	69
2016 Q2	$432K	Hold	16,070	–	–	0.04%	63
2016 Q1	$435K	Hold	16,070	–	–	0.04%	63
2015 Q4	$467K	Hold	16,070	–	–	0.04%	62
2015 Q3	$436K	Hold	16,070	–	–	0.04%	58
2015 Q2	$440K	Sell	16,070 -360	-2%	-$10.1K	0.04%	59
2015 Q1	$439K	Sell	16,430 -350	-2%	-$8.06K	0.04%	61
2014 Q4	$355K	Hold	16,780	–	–	0.03%	67
2014 Q3	$400K	Buy	16,780 +350	+2%	+$8.05K	0.03%	64
2014 Q2	$379K	Hold	16,430	–	–	0.03%	66
2014 Q1	$375K	Hold	16,430	–	–	0.03%	63
2013 Q4	$304K	Hold	16,430	–	–	0.03%	63
2013 Q3	$278K	Hold	16,430	–	–	0.03%	60
2013 Q2	$255K	Buy	+16,430	New	+$273K	0.03%	63

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Fairview Capital Investment Management's NVO Position: Q2 2026 in Review

Fairview Capital Investment Management increased its Novo Nordisk (NVO) stake by 3.1% in Q2 2026, buying an estimated $21.5K and bringing the position to 16,570 shares worth $794K. The position accounts for 0.04% of the portfolio, ranked #123.

Fairview Capital Investment Management first reported a position in NVO in Q2 2013 and has held it in 53 quarters since. The position peaked at $2.29M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Fairview Capital Investment Management held 16,570 shares of Novo Nordisk worth $794K as of Q2 2026.
Fairview Capital Investment Management bought 500 Novo Nordisk shares in Q2 2026, an estimated $21.5K.
Novo Nordisk made up 0.04% of Fairview Capital Investment Management's portfolio in Q2 2026, its #123 holding.
Fairview Capital Investment Management first reported a position in Novo Nordisk in Q2 2013 and has held it in 53 quarters since.
Fairview Capital Investment Management's Novo Nordisk position peaked at $2.29M in Q2 2024.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Fairview Capital Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.